ImmunityBio, Inc. (IBRX)
| Market Cap | 8.79B +287.3% |
| Revenue (ttm) | 165.79M +192.9% |
| Net Income | -992.36M |
| EPS | -0.99 |
| Shares Out | 1.06B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,330,218 |
| Open | 8.08 |
| Previous Close | 8.08 |
| Day's Range | 8.01 - 8.24 |
| 52-Week Range | 1.95 - 12.43 |
| Beta | 0.13 |
| Analysts | Strong Buy |
| Price Target | 12.75 (+53.8%) |
| Earnings Date | Aug 4, 2026 |
About IBRX
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient’s immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company’s platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and so... [Read more]
Financial Performance
In 2025, ImmunityBio's revenue was $113.29 million, an increase of 668.31% compared to the previous year's $14.75 million. Losses were -$351.40 million, -15.03% less than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for IBRX stock is "Strong Buy." The 12-month stock price target is $12.75, which is an increase of 53.80% from the latest price.
News
ImmunityBio appoints Kim as Vice Chairman
ImmunityBio (IBRX) announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim will serve in a newly created Office of the Executive Chairman, where he…
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that Dr. Jim Yong Kim has joined the company as Vice Chairman. Dr. Kim...
ImmunityBio reports Q2 EPS (22c) vs. (10c) last year
Reports Q2 revenue $51.2M, consensus $49.7M. “Our record quarterly net product revenue of $50.7 million and eighth consecutive quarter of sequential growth reflect continued physician adoption of ANKT...
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage biotechnology company, today announced financial and operational results for the second quarter ended June 30...
ImmunityBio Earnings release: Q2 2026
ImmunityBio released its Q2 2026 earnings on August 4, 2026, summarizing the period's financial results.
ImmunityBio Quarterly report: Q2 2026
ImmunityBio has published its Q2 2026 quarterly earnings report on August 4, 2026.
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage biotechnology company, today announced that the Emirates Drug Establishment (EDE) of th...
ImmunityBio Transcript: AGM 2026
The meeting re-elected all nine incumbent directors and ratified Deloitte & Touche LLP as auditor for 2026. No shareholder questions or additional nominations were received, and voting results will be reported to the SEC.
ImmunityBio Transcript: Jefferies Global Healthcare Conference 2026
The conference highlighted robust clinical and commercial progress for ANKTIVA, with strong efficacy and durability in bladder and lung cancer, expanding global approvals, and a growing pipeline. Financials remain solid, and new BCG strains aim to resolve shortages. Patient outcomes and physician feedback underscore transformative impact.
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced two poster presentations and one online publication at the American So...
ImmunityBio (IBRX) Facing Lawsuit After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- HBSS
SAN FRANCISCO, May 25, 2026 (GLOBE NEWSWIRE) -- ImmunityBio, Inc. (NASDAQ: IBRX) faces a securities class action lawsuit which seeks to represent investors who purchased or otherwise acquired Immunity...
ImmunityBio Inc. (NASDAQ: IBRX) Investigated for Potential Federal Securities Laws Violations – Lowey Dannenberg, P.C.
NEW YORK, May 22, 2026 (GLOBE NEWSWIRE) -- Lowey Dannenberg P.C. , a top complex litigation law firm, is investigating ImmunityBio Inc. (NASDAQ: IBRX) (“ImmunityBio” or the “Company”) for potential vi...
DEADLINE NEXT WEEK: Berger Montague Advises ImmunityBio, Inc. (IBRX) Investors to Contact the Firm Before May 26, 2026
Philadelphia, Pennsylvania--(Newsfile Corp. - May 22, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against ImmunityBio, Inc. (NASDAQ: IBRX) ("ImmunityBio" ...
ImmunityBio highlights patient survey data on NMIBC at ISPOR 2026
ImmunityBio (IBRX) announced new survey data highlighting the diverse treatment preferences and decision-making priorities of patients with Bacillus Calmette-Guerin-unresponsive high-risk non-muscle-i...
ImmunityBio presents health economic analysis on ANKTIVA plus BCG
ImmunityBio (IBRX) announced preliminary results from a new health economic analysis demonstrating that ANKTIVA plus Bacillus Calmette-Guerin achieved a lower cost per sustained complete responder com...
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced preliminary results from a new health economic analysis demonstrating ...
ImmunityBio announces FDA acceptance of supplemental BLA for ANKTIVA
ImmunityBio (IBRX) “announced that the U.S. Food and Drug Administration has accepted for review the supplemental Biologics License Application for ANKTIVA – nogapendekin alfa inbakicept-pmln – in com...
ImmunityBio Announces FDA Acceptance of Supplemental BLA for ANKTIVA® Plus BCG in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Papillary Disease; PDUFA Date Set for January 6, 2027
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the U.S. Food and Drug Administration has accepted for review the...
ImmunityBio announces results from ITC analyses of NAI with BCG
ImmunityBio (IBRX) announced results from two indirect treatment comparison analyses presented at the 2026 American Urological Association Annual Meeting evaluating nogapendekin alfa inbakicept-pmln p...
ImmunityBio Presents Favorable Comparative Effectiveness Data in Complete Response Rates of NAI + BCG Versus Nadofaragene and TAR-200 at AUA 2026
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced results from two indirect treatment comparison (...
ImmunityBio announces five U.S. patents issued for Anktiva with BCG
ImmunityBio (IBRX) announced that five United States patents have been issued to ImmunityBio covering the combination of its IL-15 receptor agonist Anktiva with Bacillus Calmette-Guerin, BCG, for the ...
ImmunityBio Announces Comprehensive U.S. Patents Covering Combination of ANKTIVA with BCG for Cancer Treatment, with Terms Through 2035
CULVER CITY, Calif.--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a vertically integrated commercial-stage immunotherapy company, today announced that five United States patents have been issued...
ImmunityBio signs exclusive U.S. agreement with Japan BCG Laboratory
ImmunityBio (IBRX) announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory, the Tokyo-based developer and manufacturer of the Tokyo strain of BCG. The agreement provides...
ImmunityBio Signs Exclusive U.S. Agreement with Japan BCG Laboratory for the Tokyo Strain of BCG to Enhance BCG Supply in the United States
WASHINGTON--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced an exclusive U.S. Development and Supply Agreement with Japan BCG Laboratory ("...
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026 AACR and ASGCT presentations showcase d...